BeNeLuxBelgiumNetherlandsLuxembourg

ActoGeniX: 20 million euros round

16.03.2007

Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Brussels – Belgian specialist for regenerative medicine TiGenix NV has raised EUR15.2m through the sale of 15.2 million shares at EUR1/share in a rights issue. Existing shareholders, who were eligible to purchase one share for...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Mechelen – Belgian drug discovery specialist Galapagos NV has sold its compound business to competitor Evotec AG. The German drug-discovery services specialist thereby acquires the affiliate Compound Focus Inc., which is key to...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

Amsterdam – European life sciences investor Life Sciences Partners (LSP) has raised EUR36m in an IPO for its first in-house fund to invest in public companies, selling 360,000 shares at EUR100/share. New shares in the fund, which...

BeNeLuxBelgiumNetherlandsLuxembourg

12.06.2011

One or zero, black or white, top or flop – digital results. Few sectors test the nerves of entrepreneurs, employees, partners and investors quite as much as biotechnology. Even if you have plenty of expertise, forecasting the...

BeNeLuxBelgiumNetherlandsLuxembourg

07.06.2011

Amsterdam – US-Dutch MolDx company Agendia N.V. has announced details of its planned IPO on NYSE Euronext in Amsterdam. The developer of microarray-based predictive diagnostics said it will issue 4,587,156 ordinary shares worth...

BeNeLuxBelgiumNetherlandsLuxembourg

31.05.2011

Amsterdam – Two studies presented at the annual conference of the European Society of Human Genetics yesterday show that common Direct-to-consumer (DTC) genetic tests give inaccurate predictions of disease risks and thus European...

BeNeLuxBelgiumNetherlandsLuxembourg

23.05.2011

Leuven – Genetically engineered poplars with less lignin grown in a field trial in Belgium deliver 81% more bio-ethanol than non-modified poplars when enzymatically digested and fermented, according to Belgian researchers headed...

BeNeLuxBelgiumNetherlandsLuxembourg

18.04.2011

Mechelen – Belgian Galapagos NV has terminated a Phase 2 study forGLP0259 in rheumatoid arthritis after an interim analysis showed the drug was not efficient. The failure affects Galapagos’ research agreement with Janssen...

BeNeLuxBelgiumNetherlandsLuxembourg

08.04.2011

Eindhoven – Researchers from Dutch imaging specialist Philips Electronics and the Eindhoven University of Technology have developed a technique that could help boost efficacy and at the same time reduce the side effects of...

BeNeLuxBelgiumNetherlandsLuxembourg

06.04.2011

Leuven – Belgian biotech TiGenix NV has agreed to merge operations with Spain-based Cellerix and raise a15m in a rights issue to expand further into regenerative medicine. TiGenix said it had agreed to combine operations though a...

Displaying results 41 to 50 out of 304

< Previous 41-50 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/4/article/actogenix-20-million-euros-round.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SILENCE THERAPEUTICS (UK)244.75 GBP4.15%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.54 EUR103.6%

FLOP

  • THROMBOGENICS (B)8.51 EUR-52.2%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 11.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events